Drugmaker Merck & Co Inc and partner Ridgeback Biotherapeutics announced today that six lab studies showed their experimental oral COVID–19 drug molnupiravir was active against the latest fast-spreading variant, Omicron.
The data evaluated the antiviral activity of the drug molnupiravir and other COVID-19 antiviral agents against specific COVID-19 variants.
The company did clarify that Molnupiravir is yet to be evaluated against Omicron in human studies.
Merck confirmed earlier this month its pill has a mechanism that can fight against any Covid variant, including Omicron.
